Velaglucerase alfa
| Clinical data | |
|---|---|
| Routes of administration | Infusion |
| ATC code | A16AB10 (WHO) |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Biological half-life | Plasma: 5–12 minutes (absorbed by macrophages) |
| Identifiers | |
| ChemSpider | none |
| UNII |
23HYE36B0I  |
| ChEMBL |
CHEMBL1201865 |
| Chemical and physical data | |
| Formula | C2532H3850N672O711S16 |
| Molar mass | 55.5 kg/mol (unglycosylated) |
 (what is this?) (verify) | |
Velaglucerase alfa (trade name VPRIV), manufactured by Shire plc is a hydrolytic lysosomal glucocerebroside-specific enzyme, which is a recombinant form of glucocerebrosidase indicated as a long-term enzyme replacement therapy for those suffering of Gaucher disease Type 1. It has an identical amino acid sequence to the naturally occurring enzyme.[1] It was approved for use by the U.S. Food and Drug Administration (FDA) on February 26, 2010.[2]
Competitive products
Imiglucerase is Genzyme's version of recombinant glucocerebrosidase. It is marketed globally under the trade name of Cerezyme.
In addition, Protalix and Pfizer have received approval for marketing taliglucerase alpha in Israel, Brazil, Canada and the U.S. The companies are expected also to file for marketing authorization in Europe and elsewhere around the world.
References
- ↑ University of Birmingham: Velaglucerase alfa for type 1 Gaucher’s disease
- ↑ Medical News Today: Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease, 27 February 2010